A global leader in serving libraries of all types, ProQuest LLC (“ProQuest”) supports the breadth of the information community with innovative discovery solutions that power the business of books and the best in research experience. More than a content provider or aggregator, ProQuest is an information partner, creating indispensable research solutions that connect people and information. Through innovative, user-centered discovery technology, ProQuest offers billions of pages of global content that includes historical newspapers, dissertations, and uniquely relevant resources for researchers of any age and sophistication—including content not likely to be digitized by others.
DrugUpdate New drug information from the publishers of MPR Oral hydromorphone in adequate pain control was achieved with once-daily dos- Increased intracranial pressure. Acute abdomen. GI surgery. extended-release form ing, patients entered a 12-week, placebo-controlled treatment Impaired renal, hepatic, thy- roid, adrenocortical, or pul- Product: Exalgo opioid-tolerant patients; that phase. In this phase, patients monary function. Gallbladder Company: Mallinckrodt is, patients who have been were randomized to receive disease. Biliary disease or Pharmacologic class: taking signiﬁcant doses of either the same dose of Exalgo, surgery. Convulsive disorders. Opioid analgesic opioids (e.g., oral morphine or Exalgo and matched pla- Delirium tremens.Toxic Active ingredient: 60 mg/day, transdermal fen- cebo in doses tapering from psychosis. Circulatory shock. Hydromorphone 8 mg, 12 tanyl 25 µg/hour, oxycodone the stable dose achieved dur- Drug abusers.Avoid abrupt mg, 16 mg; extended-release 30 mg/day, oral hydro- ing the titration phase (rescue cessation. Elderly. Debilitated. tablets; contains sulﬁtes. morphone 8 mg/day, oral doses of an immediate-relief Obstetric analgesia, labor and Indication: Moderate-to- oxymorphone 25 mg/day) product allowed). Compared delivery, nursing mothers: not severe pain when continuous for at least one week.After a to placebo, Exalgo provided recommended. Pregnancy opioid analgesia is needed single oral dose, plasma levels superior analgesia. In average (Cat. C). for an extended time period. gradually increase over six to weekly pain intensity Numeric Interactions: Not recom- Not for as-needed use or to eight hours.After that, the Rating Scale scores, there was mended within 14 days treat acute or post-op pain. concentration is sustained for a signiﬁcant difference in the of monoamine oxidase For use in opioid-tolerant 24 hours. Steady-state levels mean changes from baseline to inhibitors. Potentiation with patients only. are reached
Pages to are hidden for
"Oral hydromorphone in extended-release form"Please download to view full document